Fractyl Health (GUTS) Projected to Post Earnings on Monday

Fractyl Health (NASDAQ:GUTS) is anticipated to post its Q4 2025 resultson Monday, April 6th. Analysts expect Fractyl Health to post earnings of ($0.18) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.34. On average, analysts expect Fractyl Health to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $0.46 on Friday. The company has a debt-to-equity ratio of 3.23, a current ratio of 4.78 and a quick ratio of 4.78. Fractyl Health has a 1-year low of $0.38 and a 1-year high of $3.03. The firm has a 50 day simple moving average of $0.55 and a 200-day simple moving average of $1.26. The firm has a market cap of $72.33 million, a PE ratio of -0.25 and a beta of 1.20.

Analyst Upgrades and Downgrades

GUTS has been the subject of several research analyst reports. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Thursday, March 26th. Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $8.00 to $2.00 in a research report on Thursday, January 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GUTS. Jane Street Group LLC bought a new position in shares of Fractyl Health during the 2nd quarter valued at about $31,000. Jump Financial LLC bought a new stake in shares of Fractyl Health in the 4th quarter worth approximately $57,000. Scientech Research LLC bought a new stake in shares of Fractyl Health in the 3rd quarter worth approximately $49,000. Prelude Capital Management LLC acquired a new stake in Fractyl Health during the third quarter valued at approximately $55,000. Finally, Commonwealth Equity Services LLC acquired a new stake in Fractyl Health during the fourth quarter valued at approximately $85,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.